DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Avastin (Bevacizumab) - Summary

 

-- advertisement --

WARNINGS

GASTROINTESTINAL PERFORATIONS

AVASTIN administration can result in the development of gastrointestinal perforation, in some instances resulting in fatality. Gastrointestinal perforation, sometimes associated with intra‑abdominal abscess, occurred throughout treatment with AVASTIN (i.e., was not correlated to duration of exposure). The incidence of gastrointestinal perforation (gastrointestinal perforation, fistula formation, and/or intra‑abdominal abscess) in patients with colorectal cancer and in patients with non‑small cell lung cancer (NSCLC) receiving AVASTIN was 2.4% and 0.9%, respectively. The typical presentation was reported as abdominal pain associated with symptoms such as constipation and vomiting. Gastrointestinal perforation should be included in the differential diagnosis of patients presenting with abdominal pain on AVASTIN. AVASTIN therapy should be permanently discontinued in patients with gastrointestinal perforation. (See WARNINGS: Gastrointestinal Perforations and DOSAGE AND ADMINISTRATION: Dose Modifications.)

WOUND HEALING COMPLICATIONS

AVASTIN administration can result in the development of wound dehiscence, in some instances resulting in fatality. AVASTIN therapy should be permanently discontinued in patients with wound dehiscence requiring medical intervention. The appropriate interval between termination of AVASTIN and subsequent elective surgery required to avoid the risks of impaired wound healing⁄wound dehiscence has not been determined. (See WARNINGS: Wound Healing Complications and DOSAGE AND ADMINISTRATION: Dose Modifications.)

Hemorrhage

Fatal pulmonary hemorrhage can occur in patients with NSCLC treated with chemotherapy and AVASTIN. The incidence of severe or fatal hemoptysis was 31% in patients with squamous histology and 2.3% in patients with NSCLC excluding predominant squamous histology. Patients with recent hemoptysis (≥1⁄2 tsp of red blood) should not receive AVASTIN. (See WARNINGS: Hemorrhage, ADVERSE REACTIONS: Hemorrhage, and DOSAGE AND ADMINISTRATION: Dose Modifications.)

 

AVASTIN SUMMARY

AVASTIN®
(Bevacizumab)

AVASTIN® (Bevacizumab) is a recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF) in in vitro and in vivo assay systems. Bevacizumab contains human framework regions and the complementarity‑determining regions of a murine antibody that binds to VEGF (1).

AVASTIN®, in combination with intravenous 5‑fluorouracil‑based chemotherapy, is indicated for first- or second‑line treatment of patients with metastatic carcinoma of the colon or rectum.

AVASTIN®, in combination with carboplatin and paclitaxel, is indicated for first‑line treatment of patients with unresectable, locally advanced, recurrent or metastatic non-squamous, non-small cell lung cancer.

AVASTIN NEWS HIGHLIGHTS

Media Articles Related to Avastin (Bevacizumab)

New York Times Examines Benefits, Costs Of Cancer Drug Avastin
Source: Colorectal Cancer News From Medical News Today [2008.07.08]

Side Effects Of Sunitinib In Kidney Cancer Are 2 To 3 Times More Expensive To Manage Than Those Of Avastin Plus Interferon
Source: Statins News From Medical News Today [2008.06.02]

Avastin Added to Chemo Helps Women With Advanced Breast Cancer
Source: MedicineNet docetaxel Specialty [2008.06.02]

Combination of Cancer Drugs Linked to Anemia
Source: MedPage Today Product Alert [2008.07.16]

Geron Initiates Clinical Trial Of GRN163L In Combination With Paclitaxel And Bevacizumab In Patients With Breast Cancer
Source: Breast Cancer News From Medical News Today [2008.08.11]

more>>

Published Studies Related to Avastin (Bevacizumab)

Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. [2007.10.10]

Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial. [2007.10.05]

Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. [2007.06]

Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. [2007.04.20]

Target Practice: Lessons from Phase III Trials with Bevacizumab and Vatalanib in the Treatment of Advanced Colorectal Cancer. [2007.04]

more>>

Clinical Trials Related to Avastin (Bevacizumab)

Safety Study of Bevacizumab (Avastin) With Thoracic Radiation in Non-Small Cell Cell Lung Cancer [Recruiting]

Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer [Recruiting]

MAAM Study: Avastin and Macugen Versus Avastin Versus Macugen [Recruiting]

A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin) [Active, not recruiting]

Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma [Active, not recruiting]

more>>

Page last updated: 2008-08-11

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008